An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study
Aim. To evaluate effects of ursodeoxycholic acid (UDCA) on inflammation, steatosis and liver fibrosis and atherogenesis factors in patients with non-alcoholic fatty liver disease (NAFLD).Materials and methods. The study included 139 patients with NAFLD who received 15 mg/kg of UDCA (Ursosan®) per da...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2020-01-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/449 |
| _version_ | 1797245180058796032 |
|---|---|
| author | M. V. Mayevskaya M. Yu. Nadinskaia V. D. Lunkov I. Yu. Pirogova E. V. Chesnokov Kh. B. Kodzoeva V. T. Ivashkin |
| author_facet | M. V. Mayevskaya M. Yu. Nadinskaia V. D. Lunkov I. Yu. Pirogova E. V. Chesnokov Kh. B. Kodzoeva V. T. Ivashkin |
| author_sort | M. V. Mayevskaya |
| collection | DOAJ |
| description | Aim. To evaluate effects of ursodeoxycholic acid (UDCA) on inflammation, steatosis and liver fibrosis and atherogenesis factors in patients with non-alcoholic fatty liver disease (NAFLD).Materials and methods. The study included 139 patients with NAFLD who received 15 mg/kg of UDCA (Ursosan®) per day for 24 weeks. Before and after the study, liver function and lipid metabolism, liver steatosis index FLI, intimamedia thickness (IMT) of the carotid arteries were determined. The cardiovascular risk was calculated according to the ASCVD 2013.Results. The use of UDCA in patients with NAFLD led to a decrease in ALT (p < 0.001), AST (p < 0.001) and GGT (p < 0.001) activity; total cholesterol concentration (p < 0.001); triglycerides (p < 0.001); and LDL (p < 0.001) in the blood and the FLI liver steatosis index (p < 0.001). In addition, the rate of cardiovascular risk (p = 0.022) and IMT (р = 0.048) in women also decreased.Conclusions. The use of UDCA in NAFLD reduces the activity of inflammatory processes in the liver, its steatosis, and also improves lipid metabolism and exerts potential anti-atherogenic effects. Against the background of UDCA administration, there was no progression of liver fibrosis. None of the participants in the observational programme reached a normal body mass by the end of the program; therefore, the attained positive changes should be attributed directly to the effects of UDCA. |
| first_indexed | 2024-03-08T09:20:47Z |
| format | Article |
| id | doaj.art-38294774baf2446da71d60f33bc7c8d3 |
| institution | Directory Open Access Journal |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| last_indexed | 2024-04-24T19:22:48Z |
| publishDate | 2020-01-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj.art-38294774baf2446da71d60f33bc7c8d32024-03-25T16:53:08ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732020-01-01296222910.22416/1382-4376-2019-29-6-22-29334An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH StudyM. V. Mayevskaya0M. Yu. Nadinskaia1V. D. Lunkov2I. Yu. Pirogova3E. V. Chesnokov4Kh. B. Kodzoeva5V. T. Ivashkin6I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)Chaika Clinics Ltd.LLC MC “Lotus” Center for Gastroenterology and HepatologyTyumen State Medical UniversityI.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)Aim. To evaluate effects of ursodeoxycholic acid (UDCA) on inflammation, steatosis and liver fibrosis and atherogenesis factors in patients with non-alcoholic fatty liver disease (NAFLD).Materials and methods. The study included 139 patients with NAFLD who received 15 mg/kg of UDCA (Ursosan®) per day for 24 weeks. Before and after the study, liver function and lipid metabolism, liver steatosis index FLI, intimamedia thickness (IMT) of the carotid arteries were determined. The cardiovascular risk was calculated according to the ASCVD 2013.Results. The use of UDCA in patients with NAFLD led to a decrease in ALT (p < 0.001), AST (p < 0.001) and GGT (p < 0.001) activity; total cholesterol concentration (p < 0.001); triglycerides (p < 0.001); and LDL (p < 0.001) in the blood and the FLI liver steatosis index (p < 0.001). In addition, the rate of cardiovascular risk (p = 0.022) and IMT (р = 0.048) in women also decreased.Conclusions. The use of UDCA in NAFLD reduces the activity of inflammatory processes in the liver, its steatosis, and also improves lipid metabolism and exerts potential anti-atherogenic effects. Against the background of UDCA administration, there was no progression of liver fibrosis. None of the participants in the observational programme reached a normal body mass by the end of the program; therefore, the attained positive changes should be attributed directly to the effects of UDCA.https://www.gastro-j.ru/jour/article/view/449non-alcoholic fatty liver diseasesteatosiscardiovascular riskursodeoxycholic acidlipid metabolismatherosclerosis |
| spellingShingle | M. V. Mayevskaya M. Yu. Nadinskaia V. D. Lunkov I. Yu. Pirogova E. V. Chesnokov Kh. B. Kodzoeva V. T. Ivashkin An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study Российский журнал гастроэнтерологии, гепатологии, колопроктологии non-alcoholic fatty liver disease steatosis cardiovascular risk ursodeoxycholic acid lipid metabolism atherosclerosis |
| title | An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study |
| title_full | An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study |
| title_fullStr | An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study |
| title_full_unstemmed | An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study |
| title_short | An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study |
| title_sort | effect of ursodeoxycholic acid on inflammation steatosis and liver fibrosis and atherogenesis factors in patients with non alcoholic fatty liver disease results of the uspeh study |
| topic | non-alcoholic fatty liver disease steatosis cardiovascular risk ursodeoxycholic acid lipid metabolism atherosclerosis |
| url | https://www.gastro-j.ru/jour/article/view/449 |
| work_keys_str_mv | AT mvmayevskaya aneffectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT myunadinskaia aneffectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT vdlunkov aneffectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT iyupirogova aneffectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT evchesnokov aneffectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT khbkodzoeva aneffectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT vtivashkin aneffectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT mvmayevskaya effectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT myunadinskaia effectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT vdlunkov effectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT iyupirogova effectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT evchesnokov effectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT khbkodzoeva effectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy AT vtivashkin effectofursodeoxycholicacidoninflammationsteatosisandliverfibrosisandatherogenesisfactorsinpatientswithnonalcoholicfattyliverdiseaseresultsoftheuspehstudy |